FDA Accepts UTHR's sNDA for Inhaled Tyvaso in IPF

The FDA accepted United Therapeutics’ (UTHR) supplemental New Drug Application for nebulized Tyvaso (treprostinil) to treat idiopathic pulmonary fibrosis (IPF). The company expects the review to conclude in late April 2027. Shares closed at $492.02, giving the company a roughly $22 billion market cap.

If approved, Tyvaso would be the first inhaled treatment for IPF, a fatal scarring lung disease with a median survival of three to five years. The only approved therapies, Esbriet (pirfenidone) and Ofev (nintedanib), are both oral pills roughly a decade old that slow but do not stop decline and carry tolerability problems.

Treprostinil is a prostacyclin analog, a molecule that relaxes blood vessels and inhibits platelet aggregation. United Therapeutics argues the drug also tamps down fibrosis and inflammation in the lung, a multimodal approach that differs from Esbriet and Ofev, which act on the TGF-beta and tyrosine-kinase pathways respectively. That distinction is why the TETON trials measured forced vital capacity, a direct read on how much lung function patients keep.

The filing is supported by the TETON-1 and TETON-2 Phase 3 trials, which together randomized 1,191 patients to treprostinil or placebo over 52 weeks. Both met their primary endpoint of change in forced vital capacity and secondary endpoints including time to clinical worsening and acute exacerbation, with results published in the New England Journal of Medicine. The FDA and the European Medicines Agency have both granted treprostinil orphan designation for IPF.

For United Therapeutics, this is label-expansion arbitrage: an already-approved molecule with a decade of real-world safety data enters a large orphan indication, a materially lower-risk path than a novel drug. The inhaled route could sidestep the systemic side effects that drive patients off oral antifibrotics. The respiratory catalysts roundup frames IPF’s competitive picture, and the company’s ralinepag filing is a separate near-term catalyst.

Preserving forced vital capacity matters directly: losing lung function tracks worsening exercise tolerance and shorter survival, so the FVC endpoint the TETON trials hit is the clinical goal. The label expansion also reuses an existing commercial footprint, since Tyvaso is already sold for pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease.

The risk is that an sNDA acceptance is not an approval, and the review stretches to late April 2027. IPF is a crowded, expensive field, and rivals are also chasing the indication, so Tyvaso would face competition even if it wins the first-inhaled label.

Watch for a formal PDUFA goal date and the TETON-PPF readout in progressive pulmonary fibrosis, which is fully enrolled and would extend the franchise further.

Source: United Therapeutics sNDA acceptance press release